
Ind-Swift Limited (INDSWFTLTD.NS)
ValueMarkers Composite Index
98% below intrinsic value ($10)
Ind-Swift Limited (INDSWFTLTD.NS) — VMCI valuation read
Ind-Swift Limited (INDSWFTLTD.NS) carries a VMCI composite of 53/100, 3 points above the Healthcare sector median of 50. Among mid-cap names, that gap places INDSWFTLTD.NS in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The INDSWFTLTD.NS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads INDSWFTLTD.NS trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.6x leaves covenant headroom, the line to track on Ind-Swift Limited's next 10-Q.
INDSWFTLTD.NS rose 0.7% over the trailing 7 days, with a -15.1% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
- IDXG - Interpace Biosciences, Inc.
- IDXG - Interpace Biosciences, Inc.
- 4541.T - Nichi-Iko Pharmaceutical Co., Ltd.
- MHUAF - Meihua International Medical Technologies Co., Ltd.
- MHUAF - Meihua International Medical Technologies Co., Ltd.
- XII.JO - Numeral Limited
- INDSWFTLTD.BO - Ind-Swift Limited
- AIKI - AIkido Pharma Inc.